CLINICAL EFFICACY AND SAFETY OF AMLODIPINE/BISOPROLOL/PERINDOPRIL SINGLE-PILL AND FREE COMBINATION THERAPY IN PATIENTS WITH UNCONTROLLED ESSENTIAL HYPERTENSION. (June 2022)

• Record Type: Journal Article
• Authors: Konradi, Alexandra; Hassan, Hasnaa; Lefay, Didier; Isachenko, Elena; Jamois, Aude
• Is Part Of: Journal of hypertension. Volume 40(2022)Supplement 1
• Page Start: e303
• Publication Date: 2022-06
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000838684.83670.d8
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: Efficacy and safety of the triple therapy amlodipine 5 mg, bisoprolol 5 mg and perindopril 5 mg in single pill combination (SPC) and in free combination, over a 12-week period. Design and method: Multicenter, randomized, open-label, controlled, phase III study. Patients with uncontrolled hypertension (Systolic Blood Pressure (SBP) > = 140 and < 160mmHg and Diastolic Blood Pressure (DBP) > = 90 and < 100 mmHg) treated either by monotherapy at maximal dose or bitherapy at initial dose were randomized to the SPC (group A), or to the free combination (group B). Previous antihypertensive treatment was discontinued. Efficacy assessments: SBP, DBP, response to treatment (rate of patients with BP normalized and/or decrease of SBP > = 20 mmHg and/or decrease of DBP > = 10 mmHg from baseline) and BP control rate (SBP < 140 mmHg and DBP < 90 mmHg). Patient-reported outcomes were evaluated using the TSQM-9 (Treatment Satisfaction Questionnaire for Medication) to assess treatment effectiveness, convenience and global satisfaction at the end of the study. Results: 150 patients were randomized (mean age 55.2 ± 10.1 years). At baseline, mean SBP/DBP in the included population were 149.71 ± 5.09/94.92 ± 2.78 mmHg. After 12 weeks of treatment, important SBP/DBP decrease was observed in both groups (-22.01 ± 10.04/-13.79 ± 7.47 mmHg in group A and -21.81 ± 9.41/-15.06 ± 8.31 mmHg in group B). High response to treatment was observed in both groups (90.91% in group A, 93.06% in group B) but higher proportion of patients were controlled with SPC (91.89% in group A, 87.5% in group B). Treatments were well tolerated. Less treatment-related adverse events were reported in group A (1.3%) versus in group B (6.9%). Most of the patients were satisfied with treatment in both groups, with a better convenience for the group A. Conclusions: In case of uncontrolled BP despite monotherapy at maximal dose or bitherapy at initial dose, switching to triple therapy of amlodipine 5mg+bisoprolol 5mg+perindopril 5 mg leads to a significant decrease of BP (p < 0.001), an improvement of response to treatment and better BP control rate. For similar efficacy, treatment by SPC showed lower rate of treatment-related adverse events and was assessed as more convenient by patients as compared to free combination.